# Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2020

- Company: [Can-Fite BioPharma Ltd.](/companies/canf.md) (CIK 1536196)
- Form: 20-F
- Filed: 2021-03-25
- Accepted by EDGAR: Mar 25, 2021, 08:40 ET
- Period: 2020-12-31
- Accession: 0001213900-21-017630
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1536196/000121390021017630/f20f2020_canfitebiopharma.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1536196/000121390021017630/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2020-01-01 to 2020-12-31 | $763.0k | us-gaap:Revenues |
| Research and development | 12 months, 2020-01-01 to 2020-12-31 | $12.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2020-01-01 to 2020-12-31 | −$14.1m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months, 2020-01-01 to 2020-12-31 | −$14.4m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months, 2020-01-01 to 2020-12-31 | −$12.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2020-01-01 to 2020-12-31 | $26.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-12-31 | $8.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-12-31 | $9.4m | us-gaap:AssetsCurrent |
| Total assets | at 2020-12-31 | $9.5m | us-gaap:Assets |
| Current liabilities | at 2020-12-31 | $1.3m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2020-12-31 | $6.1m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2020-12-31 | 463,769,463 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1536196/000121390021017630/f20f2020_canfitebiopharma.htm

Filed Mar 25, 2021.
Source: SEC EDGAR, the filing index for accession 0001213900-21-017630. Last ingested by Listed: Nov 9, 2026, 17:23 ET. No prices; not investment advice.